| Literature DB >> 36185679 |
Khunsha Shakeel1, Roshina Rabail1, Sabrina Sehar1, Asad Nawaz2, Muhammad Faisal Manzoor3, Noman Walayat4, Claudia Terezia Socol5, Cristina Maria Maerescu5, Rana Muhammad Aadil1.
Abstract
Camel milk is known as the white gold of the desert because it contains within it a variety of nutrients which play a key role in the human diet. The health benefits of camel milk have been described for a variety of diseases such as diabetes, kidney disease, hepatitis, etc. including improved overall survival. A major health burden worldwide is liver diseases, and the ninth leading cause of death in Western countries is due to liver cirrhosis. Treatment is mostly ineffective for cirrhosis, fatty liver, and chronic hepatitis which are the most common diseases of the liver; furthermore current treatments carry the risk of side effects, and are often extremely expensive, particularly in the developing world. A systematic review of studies was performed to determine the association of consumption of camel milk on multiple diseases of the liver. The impact of camel milk on the laboratory tests related to the liver disorders, viral hepatitis, non-alcoholic fatty liver disease (NAFLD), cirrhosis, and hepatocellular carcinoma (HCC) were evaluated. The consumption of camel milk was accompanied by modulation of the values of serum gamma-glutamyl transferase, aspartate aminotransferase, and alanine aminotransferase in persons who are at risk of liver disease. In the patients with chronic liver disease, it was observed that they have low rates of mortality and low chances of progression to cirrhosis when they consume camel milk. Therefore, in patients with liver diseases, the addition of camel milk to their normal daily diet plan should be encouraged. In this review, camel milk's impact on the different kinds of liver diseases or any disorder associated with liver functioning was evaluated. Camel milk has a therapeutic as well as a preventive role in the maintenance and improving the metabolic regulations of the body.Entities:
Keywords: camel milk; cirrhosis; hepatitis; hepatocellular carcinoma; liver disorders; non-alcoholic fatty liver disease
Year: 2022 PMID: 36185679 PMCID: PMC9520982 DOI: 10.3389/fnut.2022.944842
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
The nutritional components of camel milk.
|
|
|
|
|---|---|---|
| Lactose | 49.8 g/l | ( |
| Fat | 35.6 g/l | |
| Polyphenols | 35.45 mg GAE/1 | |
| Protein | 32.6 g/l | |
| Flavonoids | 29.05 mg EQ/1 | |
| Vitamin C | 27.53 mg/l | |
| Ashes | 8.06 g/l |
Mechanism of action of bioactive components of camel milk.
|
|
|
|
|---|---|---|
| Lactoferrin | • Monocytes or macrophages and granulocytes are upregulated | ( |
| Whey protein concentrate | • Minimizes the effect of viral load reducing | ( |
| Immunoglobulin | • Ability to enter ins tissues and cells | ( |
| Ascorbic acid | • Helps in improving liver function | ( |
| Vitamin B, C, and E | • Act as an antioxidant | ( |
| Low lipid content | • The high value of L-carnitine | ( |
| Camel milk proteins | • Protection of non-alcoholic fatty liver diseases | ( |
| Lactoferrin | • Inhibitory effect on HCV | ( |
| Magnesium | • Delays the aging process of skin | ( |
| Zinc | • Alcoholic liver disease is improved | ( |
Scientific studies explain the hepatoprotectiveness of camel milk.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 2022 | Camel milk and camel urine | 24 Mice divided into 4 groups | Hepatotoxicity | G1 = control, G2 = positive CCL4, G3 = camel milk (100 ml/day/cage) injected with CCL4, G4 = camel Urine (100 ml/day/cage) injected with CCL4 | There is a defensive function of camel milk and camel urine against hepatotoxicity induced with CCL4 | ( |
| 2021 | Camel's milk | Adult female Sprague Dawley rats = 100 | Hepatotoxicity | G1 = Oral dose of MXC 200 mg/kg BW (methoxychlor-induced liver damage), G2= (100 mL/day) camel milk given for 6 or 12 months, G3: daily dose of (100 mL/day) for 6 or 12 months | There is protecting role of camel milk against methoxychlor-induced liver damage | ( |
| 2021 | Probiotics from camel milk | Mice = 40 | Liver injury | Model groups = skimmed camel milk, Metformin group= 0.3 g per kg BW metformin. | The liver and kidney damage is improved with camel milk probiotics that regulate lipid metabolism, and protection in mice | ( |
| 2021 | Camel whey protein hydrolysates (CWPH) | TAA- toxicity induced male Wistar albino rats=35 | Hepatorenal failure | G1 = 5 mL sterile distilled water; G2 = TAA (200 mg/kg BW), G3 = TAA (200 mg/kg BW) + CWPH (50 mg/kg BW/day orally, G4 = TAA (200 mg/kg BW) + CWPH (100 mg/kg BW/day orally, G5 = TAA (200 mg/kg BW) + CWPH 200 mg/kg BW/day orally | CWPH has hepatorenal protective properties | ( |
| 2021 | Camel milk antibodies | Male Wister rats | Hepatocellular carcinoma | Hepatocarcinoma induced by DENA + CCl4
| IgG from camel milk in the removal of dysfunction of liver cells oxidative stress induced by DENA | ( |
| 2021 | Camel milk | Albino rats =96 | Hepatotoxicity | G1: saline solution, All remaining groups: camel milk 2, 4, and 6 ml/100 g BW, respectively | Camel milk ingestion resulted in restorations of functions of kidney and liver biomarkers | ( |
| 2020 | Camel milk | Mice = 24 | Alcoholic liver disease | G1 (control group) = normal diet + 0.3 mL water, G2 (ethanol group) =normal diet + 0.3 mL water, G3 (Camel milk treatment group) = ethanol + camel milk and skimmed camel milk powder | Camel milk protects against liver injury caused by alcohol | ( |
| 2019 | Camel milk lactoferrin | Male Sprague Dawley rats = 75 | Hepatic fibrosis | CCL4+ 40% CCL4 (mix with olive oil) at 200 uL/100 g BW. Among all groups 30, 60, and 90 mg/kg/BW given with standard diet + lactoferrin orally | Camel milk lactoferrin improved blood levels of ALP, AST, bilirubin, serum urea, and serum creatinine levels | ( |
| 2019 | LAB from camel milk | Mice | Liver disease | Mice were given six strains of LAB for 7 weeks | Probiotics from camel act as a liver injury inhibitor | ( |
| 2018 | Camel milk + NSO | Female albino Wister rats=30 | Hepatotoxicity | G1 = normal control, G2 = toxic control, G3, G4, and G5 = camel milk, NSO, and NSO+ camel milk, respectively. Group VI = Unani medicine Jigreen | Protective effects of camel milk, and camel milk + | ( |
| 2018 | FCM | Male rats = 42 | Non-alcoholic fatty liver disease | G1 = standard diet, G2 = HFDHFr to induce fatty liver disease | FCM containing microencapsulated probiotics with plant extract reduced the severity of fatty liver | ( |
| 2018 | FCM | Female Wister mice = 56 | Liver damage | Control mice= water+ standard diet | FCM in combination + with | ( |
| 2018 | FCM | Human (adults) | Liver enzymes status | Overweight/obese adolescents were given camel milk 250 cc per day for 8 weeks, then diluted Cow milk yogurt 250 cc per day for 8 weeks or vice versa | FCM can be given as a functional food supplement | ( |
| 2018 | Camel milk | Rats = 30 | Hepatotoxicity | G1 = 0.5 ml normal saline, G2 = 3 g/kg/day ethanol, G3 = 1 mL/kg/day/orally camel milk, G4 = ethanol (3 g/kg/day) + camel milk (1 mL/kg/day), G5 = ethanol (3 g/kg/day) group | Camel milk has a protective and prophylactic effect against liver toxicity induced by ethanol | ( |
| 2017 | Camel milk yogurt enriched with fig and honey | Male albino rats = 47 | Steatohepatitis | G1 = +ve control MCDD, G2 = MCDD + Camel milk yogurt 30%, G3, G4, and G5 were given MCDD with 30% camel milk yogurt+ fig and honey, respectively | Protective effect on steatohepatitis | ( |
| 2017 | Camel milk+ EVOO | Mice | Liver toxicity | G1 = Acetaminophen (500 mg/kg), G2 = camel milk (33 ml/kg), G3 = extra virgin olive oil (1.7 ml/kg), G4 = acetaminophen (500 mg/kg), G5 = camel milk +acetaminophen | Olive oil and camel milk have hepatoprotective action | ( |
| 2017 | Camel milk given with drug cisplatin | Male rats = 56 | Hepatocarcinogenesis | G1 = control group, G5, G6, G7, and G8 = DENA (200 mg/kg BW) and phenobarbitone (500 ppm) in drinking water, G2, G3, G4, G7, and G8 = Camel milk (5 mL/day) and cisplatin (5 mg/kg/3 weeks) | Reduction in the hepatocarcinogenesis with camel milk intake | ( |
| 2017 | Camel milk + Peg IFN/RBV) | Human (adult patients) = 45 | Chronic hepatitis C | G1 = ( | Camel milk + Peg IFN/RBV improve the viral response + harmful effects of chronic hepatitis C are reduced | ( |
| 2017 | Camel milk | Human= 17 patients (12 male + 5 females | Hepatitis C | Control = Three healthy adults included in study | Camel milk decreased the viral load in the patient's sera | ( |
| 2017 | Camel milk | Male Wister rats = 30 | Altered liver enzymes | G1 = distilled water, G2 = induced with P407, G3 = induced with P407 then given atorvastatin (20 mg/kg), G4,5,6 = induced with P407 then camel milk 250, 500, and 1,000 mg/kg | Hepatoprotective effect of camel milk | ( |
| 2017 | Camel milk in anti-tuberculous drugs | Male albino rats = 24 | Hepatotoxicity | Rats were given a standard diet+ anti-tuberculous drugs+ camel milk | The toxicity and damage to the liver caused by anti-tuberculous drugs will be decreased with camel milk | ( |
| 2016 | Camel milk + bee honey | Male rats = 36 | Liver cirrhosis | G1 (control) = basal diet + tap water, G2 = basal diet + water intoxicated with CCL4, G3 = basal diet + camel milk, G4 = basal diet + camel milk + bee honey | Protecting effect of camel milk against CCL4-induced liver damage. | ( |
| 2016 | Camel milk | Male adult Rats = 24 | Liver injury | G1 = corn oil, G2 = water + CCL4 in a dose of 1 ml/kg in 50% corn oil, G3 = camel milk + corn oil, G4 = camel's milk+ CCL4 in a dose of 1 ml/kg 50% in corn oil. | Camel milk protects the liver and kidney against CCL4−generated oxidative stress and injuries | ( |
FCM, fermented camel milk; HFDHFr, high-fat diet and high fructose in water; Peg IFN/RBV, pegylated interferon and ribavirin; EVOO, extra virgin olive oil; LAB, lactic acid bacteria; NSO, nigella sativa oil; MCC, methionine choline-deficient diet; DENA, diethyl-nitrosamine.
Figure 1Effect of camel milk in combination with drug treatment.
Figure 2Effect of camel milk on liver carcinoma.
Figure 3Effect of camel milk on alcoholic liver disease.